These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31812677)

  • 1. Development and preclinical pharmacology of a novel dCK inhibitor, DI-87.
    Poddar S; Capparelli EV; Rosser EW; Gipson RM; Wei L; Le T; Jung ME; Radu C; Nikanjam M
    Biochem Pharmacol; 2020 Feb; 172():113742. PubMed ID: 31812677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.
    Kim W; Le TM; Wei L; Poddar S; Bazzy J; Wang X; Uong NT; Abt ER; Capri JR; Austin WR; Van Valkenburgh JS; Steele D; Gipson RM; Slavik R; Cabebe AE; Taechariyakul T; Yaghoubi SS; Lee JT; Sadeghi S; Lavie A; Faull KF; Witte ON; Donahue TR; Phelps ME; Herschman HR; Herrmann K; Czernin J; Radu CG
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4027-32. PubMed ID: 27035974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
    Blackstock AW; Lightfoot H; Case LD; Tepper JE; Mukherji SK; Mitchell BS; Swarts SG; Hess SM
    Clin Cancer Res; 2001 Oct; 7(10):3263-8. PubMed ID: 11595723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
    Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
    J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel PET probes specific for deoxycytidine kinase.
    Shu CJ; Campbell DO; Lee JT; Tran AQ; Wengrod JC; Witte ON; Phelps ME; Satyamurthy N; Czernin J; Radu CG
    J Nucl Med; 2010 Jul; 51(7):1092-8. PubMed ID: 20554721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression and activity of thymidine kinase 1 and deoxycytidine kinase are modulated by hydrogen peroxide and nucleoside analogs.
    Sun R; Eriksson S; Wang L
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1347-1358. PubMed ID: 32189555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells.
    Smal C; Cardoen S; Bertrand L; Delacauw A; Ferrant A; Van den Berghe G; Van Den Neste E; Bontemps F
    Biochem Pharmacol; 2004 Jul; 68(1):95-103. PubMed ID: 15183121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.
    Guantay L; Garro C; Siri S; Pansa MF; Ghidelli-Disse S; Paviolo N; Racca A; Nicotra V; Radu C; Bocco JL; Felice R; Jansson KH; Remlinger K; Amador A; Stronach E; Coleman K; Muelbaier M; Drewes G; Gloger I; Madauss K; García M; Gottifredi V; Soria G
    Drug Resist Updat; 2023 Mar; 67():100932. PubMed ID: 36706533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.
    Murphy JM; Armijo AL; Nomme J; Lee CH; Smith QA; Li Z; Campbell DO; Liao HI; Nathanson DA; Austin WR; Lee JT; Darvish R; Wei L; Wang J; Su Y; Damoiseaux R; Sadeghi S; Phelps ME; Herschman HR; Czernin J; Alexandrova AN; Jung ME; Lavie A; Radu CG
    J Med Chem; 2013 Sep; 56(17):6696-708. PubMed ID: 23947754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
    Hodzic J; Giovannetti E; Diosdado B; Adema AD; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1214-22. PubMed ID: 22132977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Special function of deoxycytidine kinase (dCK) in the activation of chemotherapeutic nucleoside analogs and in the inhibition of cell proliferation].
    Staub M
    Magy Onkol; 2004; 48(3):229-34. PubMed ID: 15520873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.
    Nomme J; Li Z; Gipson RM; Wang J; Armijo AL; Le T; Poddar S; Smith T; Santarsiero BD; Nguyen HA; Czernin J; Alexandrova AN; Jung ME; Radu CG; Lavie A
    J Med Chem; 2014 Nov; 57(22):9480-94. PubMed ID: 25341194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
    Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
    Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity.
    Ge Y; Jensen TL; Matherly LH; Taub JW
    J Biol Chem; 2003 Dec; 278(50):49901-10. PubMed ID: 14514691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.